Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain

Autonomix Medical, Inc.

All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.
100% of responding patients zero opioid use at 7 days post-procedure; 73% remained opioid-free at 4-6 weeks follow-up.
No device- or procedure-related serious adverse events; 6 subjects died from disease progression unrelated to the procedure.
PoC2 phase begins Q2 2025, targeting additional visceral cancers (liver, gall bladder, bile duct) and earlier-stage pancreatic cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.